-
1
-
-
6044226542
-
Preoperative versus postoperative chemoradiotherapy for rectal cancer
-
Sauer R., Becker H., Hohenberger W., et al. Preoperative versus postoperative chemoradiotherapy for rectal cancer. N Engl J Med 351 (2004) 1731-1740
-
(2004)
N Engl J Med
, vol.351
, pp. 1731-1740
-
-
Sauer, R.1
Becker, H.2
Hohenberger, W.3
-
2
-
-
39749153032
-
Phase I-II trial of cetuximab, capecitabine, oxaliplatin, and radiotherapy as preoperative treatment in rectal cancer
-
Rodel C., Arnold D., Hipp M., et al. Phase I-II trial of cetuximab, capecitabine, oxaliplatin, and radiotherapy as preoperative treatment in rectal cancer. Int J Radiat Oncol Biol Phys 70 (2008) 1081-1086
-
(2008)
Int J Radiat Oncol Biol Phys
, vol.70
, pp. 1081-1086
-
-
Rodel, C.1
Arnold, D.2
Hipp, M.3
-
3
-
-
33644842988
-
Prognostic significance of tumor regression after preoperative chemoradiotherapy for rectal cancer
-
Rodel C., Martus P., Papadoupolos T., et al. Prognostic significance of tumor regression after preoperative chemoradiotherapy for rectal cancer. J Clin Oncol 23 (2005) 8688-8696
-
(2005)
J Clin Oncol
, vol.23
, pp. 8688-8696
-
-
Rodel, C.1
Martus, P.2
Papadoupolos, T.3
-
4
-
-
45049088412
-
Prognostic value of pathologic complete response after neoadjuvant therapy in locally advanced rectal cancer: long-term analysis of 566 ypCR patients
-
Capirci C., Valentini V., Cionini L., et al. Prognostic value of pathologic complete response after neoadjuvant therapy in locally advanced rectal cancer: long-term analysis of 566 ypCR patients. Int J Radiat Oncol Biol Phys 72 (2008) 99-107
-
(2008)
Int J Radiat Oncol Biol Phys
, vol.72
, pp. 99-107
-
-
Capirci, C.1
Valentini, V.2
Cionini, L.3
-
5
-
-
33750360895
-
Combined vascular endothelial growth factor-targeted therapy and radiotherapy for rectal cancer: Theory and clinical practice
-
Willett C.G., Kozin S.V., Duda D.G., et al. Combined vascular endothelial growth factor-targeted therapy and radiotherapy for rectal cancer: Theory and clinical practice. Semin Oncol 33 5 Suppl. 10 (2006) S35-S40
-
(2006)
Semin Oncol
, vol.33
, Issue.5 SUPPL. 10
-
-
Willett, C.G.1
Kozin, S.V.2
Duda, D.G.3
-
6
-
-
33751169352
-
Phase I trial of cetuximab in combination with capecitabine, weekly irinotecan, and radiotherapy as neoadjuvant therapy for rectal cancer
-
Hofheinz R.D., Horisberger K., Woernle C., et al. Phase I trial of cetuximab in combination with capecitabine, weekly irinotecan, and radiotherapy as neoadjuvant therapy for rectal cancer. Int J Radiat Oncol Biol Phys 66 (2006) 1384-1390
-
(2006)
Int J Radiat Oncol Biol Phys
, vol.66
, pp. 1384-1390
-
-
Hofheinz, R.D.1
Horisberger, K.2
Woernle, C.3
-
7
-
-
0034989658
-
Developmental roles of platelet-derived growth factors
-
Betsholtz C., Karlsson L., and Lindahl P. Developmental roles of platelet-derived growth factors. Bioessays 23 (2001) 494-507
-
(2001)
Bioessays
, vol.23
, pp. 494-507
-
-
Betsholtz, C.1
Karlsson, L.2
Lindahl, P.3
-
8
-
-
0026551550
-
Genomic organization of the human c-kit gene: Evolution of the receptor tyrosine kinase subclass III
-
Andre C., Martin E., Cornu F., et al. Genomic organization of the human c-kit gene: Evolution of the receptor tyrosine kinase subclass III. Oncogene 7 (1992) 685-691
-
(1992)
Oncogene
, vol.7
, pp. 685-691
-
-
Andre, C.1
Martin, E.2
Cornu, F.3
-
9
-
-
7444269880
-
Expression of the proto-oncogene c-KIT in normal and tumor tissues from colorectal carcinoma patients
-
Sammarco I., Capurso G., Coppola L., et al. Expression of the proto-oncogene c-KIT in normal and tumor tissues from colorectal carcinoma patients. Int J Colorectal Dis 19 (2004) 545-553
-
(2004)
Int J Colorectal Dis
, vol.19
, pp. 545-553
-
-
Sammarco, I.1
Capurso, G.2
Coppola, L.3
-
10
-
-
34250814096
-
KIT/stem cell factor expression in premalignant and malignant lesions of the colon mucosa in relationship to disease progression and outcomes
-
Bellone G., Smirne C., Carbone A., et al. KIT/stem cell factor expression in premalignant and malignant lesions of the colon mucosa in relationship to disease progression and outcomes. Int J Oncol 29 (2006) 851-859
-
(2006)
Int J Oncol
, vol.29
, pp. 851-859
-
-
Bellone, G.1
Smirne, C.2
Carbone, A.3
-
11
-
-
26944437515
-
PDGFRbeta+ perivascular progenitor cells in tumours regulate pericyte differentiation and vascular survival
-
Song S., Ewald A.J., Stallcup W., et al. PDGFRbeta+ perivascular progenitor cells in tumours regulate pericyte differentiation and vascular survival. Nat Cell Biol 7 (2005) 870-879
-
(2005)
Nat Cell Biol
, vol.7
, pp. 870-879
-
-
Song, S.1
Ewald, A.J.2
Stallcup, W.3
-
12
-
-
33749441325
-
Rapid vascular regrowth in tumors after reversal of VEGF inhibition
-
Mancuso M.R., Davis R., Norberg S.M., et al. Rapid vascular regrowth in tumors after reversal of VEGF inhibition. J Clin Invest 116 (2006) 2610-2621
-
(2006)
J Clin Invest
, vol.116
, pp. 2610-2621
-
-
Mancuso, M.R.1
Davis, R.2
Norberg, S.M.3
-
13
-
-
34547643983
-
Targeting the expression of platelet-derived growth factor receptor by reactive stroma inhibits growth and metastasis of human colon carcinoma
-
Kitadai Y., Sasaki T., Kuwai T., et al. Targeting the expression of platelet-derived growth factor receptor by reactive stroma inhibits growth and metastasis of human colon carcinoma. Am J Pathol 169 (2006) 2054-2065
-
(2006)
Am J Pathol
, vol.169
, pp. 2054-2065
-
-
Kitadai, Y.1
Sasaki, T.2
Kuwai, T.3
-
14
-
-
13444257366
-
Antiangiogenic and antitumor activity of a selective PDGFR tyrosine kinase inhibitor, CP-673,451
-
Roberts W.G., Whalen P.M., Soderstrom E., et al. Antiangiogenic and antitumor activity of a selective PDGFR tyrosine kinase inhibitor, CP-673,451. Cancer Res 65 (2005) 957-966
-
(2005)
Cancer Res
, vol.65
, pp. 957-966
-
-
Roberts, W.G.1
Whalen, P.M.2
Soderstrom, E.3
-
15
-
-
20044396551
-
Blockade of platelet-derived growth factor receptor-beta by CDP860, a humanized, PEGylated di-Fab', leads to fluid accumulation and is associated with increased tumor vascularized volume
-
Jayson G.C., Parker G.J.M., Mullamitha S., et al. Blockade of platelet-derived growth factor receptor-beta by CDP860, a humanized, PEGylated di-Fab', leads to fluid accumulation and is associated with increased tumor vascularized volume. J Clin Oncol 23 (2005) 973-981
-
(2005)
J Clin Oncol
, vol.23
, pp. 973-981
-
-
Jayson, G.C.1
Parker, G.J.M.2
Mullamitha, S.3
-
16
-
-
0032875460
-
Mechanism of action and in vivo role of platelet-derived growth factor
-
Heldin C.-H., and Westermark B. Mechanism of action and in vivo role of platelet-derived growth factor. Physiol Rev 79 (1999) 1283-1316
-
(1999)
Physiol Rev
, vol.79
, pp. 1283-1316
-
-
Heldin, C.-H.1
Westermark, B.2
-
18
-
-
0036790060
-
Inhibition of PDGF receptor signaling in tumor stroma enhances antitumor effect of chemotherapy
-
Pietras K., Rubin K., Sjoblom T., et al. Inhibition of PDGF receptor signaling in tumor stroma enhances antitumor effect of chemotherapy. Cancer Res 62 (2002) 5476-5484
-
(2002)
Cancer Res
, vol.62
, pp. 5476-5484
-
-
Pietras, K.1
Rubin, K.2
Sjoblom, T.3
-
19
-
-
38349081290
-
Harmonization of BCR-ABL mRNA quantification using a uniform multifunctional control plasmid in 37 international laboratories
-
Muller M.C., Erben P., Saglio G., et al. Harmonization of BCR-ABL mRNA quantification using a uniform multifunctional control plasmid in 37 international laboratories. Leukemia 22 (2008) 96-102
-
(2008)
Leukemia
, vol.22
, pp. 96-102
-
-
Muller, M.C.1
Erben, P.2
Saglio, G.3
-
21
-
-
0038476608
-
Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors
-
Bergers G., Song S., Meyer-Morse N., et al. Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors. J Clin Invest 111 (2003) 1287-1295
-
(2003)
J Clin Invest
, vol.111
, pp. 1287-1295
-
-
Bergers, G.1
Song, S.2
Meyer-Morse, N.3
-
22
-
-
34247848503
-
The role of PDGF in radiation oncology
-
Li M., Jendrossek V., and Belka C. The role of PDGF in radiation oncology. Radiat Oncol 2 (2007) 5
-
(2007)
Radiat Oncol
, vol.2
, pp. 5
-
-
Li, M.1
Jendrossek, V.2
Belka, C.3
-
23
-
-
34047179551
-
Phase I/II study of preoperative cetuximab, capecitabine, and external beam radiotherapy in patients with rectal cancer
-
Machiels J.P., Sempoux C., Scalliet P., et al. Phase I/II study of preoperative cetuximab, capecitabine, and external beam radiotherapy in patients with rectal cancer. Ann Oncol 18 (2007) 738-744
-
(2007)
Ann Oncol
, vol.18
, pp. 738-744
-
-
Machiels, J.P.1
Sempoux, C.2
Scalliet, P.3
-
24
-
-
24944465683
-
Preoperative concurrent radiotherapy with capecitabine before total mesorectal excision in locally advanced rectal cancer
-
Kim J.C., Kim T.W., Kim J.H., et al. Preoperative concurrent radiotherapy with capecitabine before total mesorectal excision in locally advanced rectal cancer. Int J Radiat Oncol Biol Phys 63 (2005) 346-353
-
(2005)
Int J Radiat Oncol Biol Phys
, vol.63
, pp. 346-353
-
-
Kim, J.C.1
Kim, T.W.2
Kim, J.H.3
-
25
-
-
34247180454
-
Multicenter phase II trial of chemoradiation with oxaliplatin for rectal cancer
-
Rodel C., Liersch T., Hermann R.M., et al. Multicenter phase II trial of chemoradiation with oxaliplatin for rectal cancer. J Clin Oncol 25 (2007) 110-117
-
(2007)
J Clin Oncol
, vol.25
, pp. 110-117
-
-
Rodel, C.1
Liersch, T.2
Hermann, R.M.3
-
26
-
-
33947425624
-
A phase II study of capecitabine and irinotecan in combination with concurrent pelvic radiotherapy (CapIri-RT) as neoadjuvant treatment of locally advanced rectal cancer
-
Willeke F., Horisberger K., Kraus-Tiefenbacher U., et al. A phase II study of capecitabine and irinotecan in combination with concurrent pelvic radiotherapy (CapIri-RT) as neoadjuvant treatment of locally advanced rectal cancer. Br J Cancer 96 (2007) 912-917
-
(2007)
Br J Cancer
, vol.96
, pp. 912-917
-
-
Willeke, F.1
Horisberger, K.2
Kraus-Tiefenbacher, U.3
-
27
-
-
33750209783
-
Treatment with imatinib in NSCLC is associated with decrease of phosphorylated PDGFR-beta and VEGF expression, decrease in interstitial fluid pressure and improvement of oxygenation
-
Vlahovic G., Rabbani Z.N., Herndon II J.E., et al. Treatment with imatinib in NSCLC is associated with decrease of phosphorylated PDGFR-beta and VEGF expression, decrease in interstitial fluid pressure and improvement of oxygenation. Br J Cancer 95 (2006) 1013-1019
-
(2006)
Br J Cancer
, vol.95
, pp. 1013-1019
-
-
Vlahovic, G.1
Rabbani, Z.N.2
Herndon II, J.E.3
|